Background: Intravitreal (IV) bevacizumab (Avastin®, Roche), initially used for the off-label treatment of neovascular age-related macular degeneration (AMD), has extended itself to treat various ocular pathologies such as choroidal neovascularization not associated to AMD. Methods: IV bevacizumab 1,25 mg (Avastin) was used in the treatment of choroidal neovascularization (CNV) in 6 eyes of 5 patients with angioid streaks. All cases had a history of photodynamic treatment (PDT) or laser treatment and all showed progressive worsening despite the use of these therapies. Results: After injection patients were followed up at nearly 2-month intervals. IV Avastin was repeated in case of recurrence. Three eyes were treated combining PDT and IV Avastin. Cases were followed up for 7–14 months. All patients needed more IV injections. Five out of 6 eyes showed an improvement of BCVA and a slight reduction of leakage and size with FA. Conclusion: This small series suggests that IV Avastin might be useful in the treatment of CNV due to AS.

Keywords:
Angioid streaks, Bevacizumab, Choroidal neovascularization, Intravitreal injection
1.
Mansour AM, Shields JA, Annesley WH Jr, et al: Macular degeneration in angioid streaks. Ophthalmologica 1988;197:36–41.
2.
Piro PA, Scheraga D, Fine SL: Angioid streaks: Natural history and visual prognosis; in Fine SL, Owens SL (eds): Management of Retinal Vascular and Macular Disorders. Baltimore, Williams & Wilkins, 1983, pp 136–139.
3.
Pece A, Avanza P, Galli L, Brancato R: Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina 1997;17:12–16.
4.
Mennel S, Barbazetto I, Meyer CH, Peter S, Stur M: Ocular photodynamic therapy: standard applications and new indications. 1. Review of the literature and personal experience. Ophthalmologica 2007;221:216–226.
5.
Menchini U, Virgili G, Introini U, et al: Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy. Retina 2004;24:763–771.
6.
Teixeira A, Moraes N, Farah ME, Bonomo PP: Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 2006;84:835–836.
7.
Lommatzsch A, Spital G, Trieschmann M, Pauleikhoff D: Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks. Ophthalmologe 2007;104:325–328.
8.
Bhatnagar P, Freund KB, Spaide RF, Klancnik JM, Cooney MJ, Ho I, Fine HF, Yannuzzi LA: Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007;27:897–902.
9.
Rinaldi M, Dell’Omo R, Romano MR, Chiosi F, Cipollone U, Costagliola C: Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 2007;125:1422–1423.
10.
Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A: Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 2007;55:457–458.
11.
Holz FG, on behalf the PROTECT Study Group: Ophthalmology, University of Bonn, Bonn, Germany. Nine months safety and efficacy results from an open-label, multicenter, phase II study of same-day vertepofin and ranibizumab 0,5 mg (PROTECT Study). Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, 2007.
12.
Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133–140.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.